Antioxidants and methimazole in the treatment of Graves' disease: Effect on urinary malondialdehyde levels

We have postulated that metabolic oxidation could be the source of signs and symptoms of hyperthyroidism. The present study was designed to evaluate urinary malondialdehyde levels in Graves' disease and compare this oxidative stress biomarker with the clinical evolution of patients suffering th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Guerra, Liliana Noemí, Ríos de Molina, María del Carmen, Miler, Eliana Andrea
Publicado: 2005
Materias:
Acceso en línea:https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00098981_v352_n1-2_p115_Guerra
http://hdl.handle.net/20.500.12110/paper_00098981_v352_n1-2_p115_Guerra
Aporte de:
id paper:paper_00098981_v352_n1-2_p115_Guerra
record_format dspace
spelling paper:paper_00098981_v352_n1-2_p115_Guerra2023-06-08T14:34:05Z Antioxidants and methimazole in the treatment of Graves' disease: Effect on urinary malondialdehyde levels Guerra, Liliana Noemí Ríos de Molina, María del Carmen Miler, Eliana Andrea Hyperthyroidism Malondialdehyde Methimazole (MMI) antioxidant malonaldehyde thiamazole adult antioxidant activity article clinical article comparative study controlled study correlation analysis evaluation female Graves disease heart rate human hyperthyroidism male oxidative stress parameter priority journal Adult Antioxidants Double-Blind Method Female Follow-Up Studies Graves Disease Heart Rate Humans Male Malondialdehyde Methimazole Middle Aged Oxidative Stress We have postulated that metabolic oxidation could be the source of signs and symptoms of hyperthyroidism. The present study was designed to evaluate urinary malondialdehyde levels in Graves' disease and compare this oxidative stress biomarker with the clinical evolution of patients suffering this illness. We evaluated the concentration of urinary and serum malondialdehyde (MDA) in 36 patients with Graves' disease. Patients were treated with the antithyroid drug methimazole (MMI; Group A) or antioxidant mixture (200 mg vitamin E, 3 mg β-carotene, 250 mg vitamin C, 1 mg Cu, 7.5 mg Zn, 1.5 mg Mn, and 15 μg Se; Group B). MDA concentrations were higher in hyperthyroid patients compared to euthyroid controls, and a positive correlation was observed between serum and urinary MDA levels. Group A decreased urinary MDA to control values. There was a positive correlation between the clinical score and the heart rate of patients with urinary MDA before and during the treatment with MMI (Group A). Similar results were observed after treatment with the antioxidant mixture. Urinary MDA might be a good parameter in the follow-up of patients during MMI treatment. We proposed that oxidative stress correlates with signs and symptoms of hyperthyroidism. © 2004 Published by Elsevier B.V. Fil:Guerra, L.N. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. Fil:Ríos De Molina, M.D.C. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. Fil:Miler, E.A. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. 2005 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00098981_v352_n1-2_p115_Guerra http://hdl.handle.net/20.500.12110/paper_00098981_v352_n1-2_p115_Guerra
institution Universidad de Buenos Aires
institution_str I-28
repository_str R-134
collection Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA)
topic Hyperthyroidism
Malondialdehyde
Methimazole (MMI)
antioxidant
malonaldehyde
thiamazole
adult
antioxidant activity
article
clinical article
comparative study
controlled study
correlation analysis
evaluation
female
Graves disease
heart rate
human
hyperthyroidism
male
oxidative stress
parameter
priority journal
Adult
Antioxidants
Double-Blind Method
Female
Follow-Up Studies
Graves Disease
Heart Rate
Humans
Male
Malondialdehyde
Methimazole
Middle Aged
Oxidative Stress
spellingShingle Hyperthyroidism
Malondialdehyde
Methimazole (MMI)
antioxidant
malonaldehyde
thiamazole
adult
antioxidant activity
article
clinical article
comparative study
controlled study
correlation analysis
evaluation
female
Graves disease
heart rate
human
hyperthyroidism
male
oxidative stress
parameter
priority journal
Adult
Antioxidants
Double-Blind Method
Female
Follow-Up Studies
Graves Disease
Heart Rate
Humans
Male
Malondialdehyde
Methimazole
Middle Aged
Oxidative Stress
Guerra, Liliana Noemí
Ríos de Molina, María del Carmen
Miler, Eliana Andrea
Antioxidants and methimazole in the treatment of Graves' disease: Effect on urinary malondialdehyde levels
topic_facet Hyperthyroidism
Malondialdehyde
Methimazole (MMI)
antioxidant
malonaldehyde
thiamazole
adult
antioxidant activity
article
clinical article
comparative study
controlled study
correlation analysis
evaluation
female
Graves disease
heart rate
human
hyperthyroidism
male
oxidative stress
parameter
priority journal
Adult
Antioxidants
Double-Blind Method
Female
Follow-Up Studies
Graves Disease
Heart Rate
Humans
Male
Malondialdehyde
Methimazole
Middle Aged
Oxidative Stress
description We have postulated that metabolic oxidation could be the source of signs and symptoms of hyperthyroidism. The present study was designed to evaluate urinary malondialdehyde levels in Graves' disease and compare this oxidative stress biomarker with the clinical evolution of patients suffering this illness. We evaluated the concentration of urinary and serum malondialdehyde (MDA) in 36 patients with Graves' disease. Patients were treated with the antithyroid drug methimazole (MMI; Group A) or antioxidant mixture (200 mg vitamin E, 3 mg β-carotene, 250 mg vitamin C, 1 mg Cu, 7.5 mg Zn, 1.5 mg Mn, and 15 μg Se; Group B). MDA concentrations were higher in hyperthyroid patients compared to euthyroid controls, and a positive correlation was observed between serum and urinary MDA levels. Group A decreased urinary MDA to control values. There was a positive correlation between the clinical score and the heart rate of patients with urinary MDA before and during the treatment with MMI (Group A). Similar results were observed after treatment with the antioxidant mixture. Urinary MDA might be a good parameter in the follow-up of patients during MMI treatment. We proposed that oxidative stress correlates with signs and symptoms of hyperthyroidism. © 2004 Published by Elsevier B.V.
author Guerra, Liliana Noemí
Ríos de Molina, María del Carmen
Miler, Eliana Andrea
author_facet Guerra, Liliana Noemí
Ríos de Molina, María del Carmen
Miler, Eliana Andrea
author_sort Guerra, Liliana Noemí
title Antioxidants and methimazole in the treatment of Graves' disease: Effect on urinary malondialdehyde levels
title_short Antioxidants and methimazole in the treatment of Graves' disease: Effect on urinary malondialdehyde levels
title_full Antioxidants and methimazole in the treatment of Graves' disease: Effect on urinary malondialdehyde levels
title_fullStr Antioxidants and methimazole in the treatment of Graves' disease: Effect on urinary malondialdehyde levels
title_full_unstemmed Antioxidants and methimazole in the treatment of Graves' disease: Effect on urinary malondialdehyde levels
title_sort antioxidants and methimazole in the treatment of graves' disease: effect on urinary malondialdehyde levels
publishDate 2005
url https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00098981_v352_n1-2_p115_Guerra
http://hdl.handle.net/20.500.12110/paper_00098981_v352_n1-2_p115_Guerra
work_keys_str_mv AT guerraliliananoemi antioxidantsandmethimazoleinthetreatmentofgravesdiseaseeffectonurinarymalondialdehydelevels
AT riosdemolinamariadelcarmen antioxidantsandmethimazoleinthetreatmentofgravesdiseaseeffectonurinarymalondialdehydelevels
AT milerelianaandrea antioxidantsandmethimazoleinthetreatmentofgravesdiseaseeffectonurinarymalondialdehydelevels
_version_ 1768546095755952128